AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02004717
Drug: DS-8895a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00420095
Drug: Human insulin 30/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
Trial: NCT00393705
Drug: Insulin Biphasic Aspart 30/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
Trial: NCT02718378
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03959150
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral fluorouracil
Trial: NCT03163615
Drug: Tibet Rhodiola Capsule
RxNorm normalized name: RHODIOLA ROSEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules, po, from admission up to 84 days
Trial: NCT03163615
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules, po, from admission up to 84 days
Trial: NCT00134251
Drug: SLV308
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01835548
Drug: NT0102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT0102 (methylphenidate polistirex \[MPP\] extended release \[XR\] ODT) was given once daily at a dose equivalent to 20-60 mg methylphenidate hydrochloride.
Trial: NCT01835548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching ODT placebo was given once daily.
Trial: NCT01898845
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01896531
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive leucovorin or equivalent substitute orally, on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity.
Trial: NCT01896531
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching oral placebo capsules once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
Trial: NCT03316222
Drug: GNS561
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses to be administered 3 times a week.
Trial: NCT02190318
Drug: spirolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01380808
Drug: capecitabine and pseudomonas aeruginosa combination
RxNorm normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capecitabine 1000mg/m2 bid, po. pseudomonas aeruginosa 0.5ml loading dose,1ml qod ih.
Trial: NCT01294293
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04403971
Drug: Listerine Oral Liquid Product
RxNorm normalized name: Listerine Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention group 2 received 10ml Listerine solution for oral rinse twice a day.
Trial: NCT03247686
Drug: RSLV-132
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNase Fc fusion protein
Trial: NCT03247686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01016340
Drug: MCS
RxNorm normalized name: MCS Leg Bag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCS-5 Softgel 5 mg
Trial: NCT01520987
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).
Trial: NCT01520987
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once-daily
Trial: NCT03017352
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00855920
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
Trial: NCT01466374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline, Intravenous (IV), 0 mg, Once a week for the first week and every other week thereafter, 11 weeks
Trial: NCT01466374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline, Intravenous, 0 mg, Every other week, Up to 337days
Trial: NCT03797001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, daily for 24 weeks
Trial: NCT00001723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
Trial: NCT04658277
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the intervention arm will take Clarithromycin 250mg daily.
Trial: NCT02178124
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01948401
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chronic treatment with oral corticosteroids, high dose inhaled corticosteroids
Trial: NCT01948401
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: additional 0.5 mg/kg orally for 7 days
Trial: NCT03806127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT02435433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02583191
Drug: low-molecular heparine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH in therapeutic dosage (1-2× daily s.c.) according to standards of the individual study center, using licensed dosages, e.g.~* Enoxaparin 1 mg/kg BW twice daily~* Tinzaparin 175 I.E./kg BW once daily~* Dalteparin 200 I.E./kg BW once daily
Trial: NCT00494741
Drug: azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients randomized in this group will receive 75 mg of AZA per os (or 125 mg if body weight \> 75 kg) once a day starting on the day of transplant. AZA dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
Trial: NCT00916045
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04133116
Drug: LY3471851
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04133116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01630616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose, tablets
Trial: NCT00486434
Drug: SMC021 Oral Calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8mg SMC021 (Oral Calcitoinin) twice daily
Trial: NCT00486434
Drug: SMC021 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally, twice daily
Trial: NCT01494090
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 or 20 mg per day during 6 months
Trial: NCT01494090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 or 20 mg per day during 6 months
Trial: NCT02771054
Drug: TAF/FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change of nucleoside backbone
Trial: NCT01013818
Drug: HGS1029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
Trial: NCT03155893
Drug: SMV Placebo (Matching 150 mg SMV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SMV Placebo (matching 150 mg SMV \[2\*75 mg capsules\]) orally once daily administered from Day 1 to 16 in Treatment A, B and on Day 1 in Treatment C.
Trial: NCT02456350
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On days -5 through -3, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.
Trial: NCT00627120
Drug: VGX-1027
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.
Trial: NCT01573975
Drug: 5RA-5RCM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.
Trial: NCT01573975
Drug: 5RA-5RCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + tetracycline 1000mg b.i.d x last 5 days.
Trial: NCT02056340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04010669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 hours infusion of 1000ml Normal Saline solution 0.9%
Trial: NCT03446885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule administered orally
Trial: NCT00690885
Drug: placebo lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo lozenges
Trial: NCT01648205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be given for first month.
Trial: NCT02638727
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group treat with placebo dayley
Trial: NCT01175941
Drug: NRL001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg NRL001 in a 2 g suppository, administered once daily for 7 days
Trial: NCT01175941
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo - administered as a 2 g suppository, once daily for 7 days
Trial: NCT03236974
Drug: AZD9496
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy
Trial: NCT00438113
Drug: Aggressive Blood Pressure control
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive Blood Pressure therapy, alone or combination therapy, to reach a target BP equal to or less than 120/80 mmHg
Trial: NCT00240162
Drug: PTK787/ZK 222584
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03314402
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00064844
Drug: Placebo gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
Trial: NCT01355341
Drug: HERBMED PLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Twice day for 6 month with lunch and dinner.
Trial: NCT00296894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01010516
Drug: High-dose rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 of rosuvastatin daily
Trial: NCT00030511
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02978261
Drug: PLB1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
Trial: NCT01507597
Drug: Native human Glucagon-like Peptide-1 ( GLP-1(7-36))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous iv. infusion of the native gut hormone GLP-1 (0.2 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
Trial: NCT01507597
Drug: Native human Glucagon-like Peptide-1 ( GLP-1(7-36))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous iv. infusion of the native gut hormone GLP-1 (0.4 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
Trial: NCT01507597
Drug: Native human Glucagon-like Peptide-1 ( GLP-1(7-36))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous iv. infusion of the native gut hormone GLP-1 (0.8 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
Trial: NCT03789318
Drug: CA-008 5 mg
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg CA-008 reconstituted in saline.
Trial: NCT03789318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each cohort will use placebo reconstituted in saline.
Trial: NCT03789318
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mcg IV administered intraoperatively
Trial: NCT03789318
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg IV administered intraoperatively
Trial: NCT03789318
Drug: CA-008 10 mg
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg CA-008 reconstituted in saline.
Trial: NCT03789318
Drug: CA-008 15 mg
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg CA-008 reconstituted in saline.
Trial: NCT00364637
Drug: Total intravenous anesthesia
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03276156
Drug: Apatinib plus S-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);
Trial: NCT01386554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains the same inactive ingredients as that used for H.P. Acthar Gel without the API.~Placebo given SC for 6 months (80 U two times a week).
Trial: NCT00700661
Drug: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching-image Montelukast placebo. Duration of Treatment: 48 Weeks
Trial: NCT03391050
Drug: APR-246
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT02951195
Drug: TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablet for oral administration.
Trial: NCT02951195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-152.
Trial: NCT02951195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-152/TEZ/IVA triple combination (TC).
Trial: NCT02401139
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01310855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00397696
Drug: [123I] 5-IA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will undergo written informed consent and a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations using the MMSE, the ANAM computerized cognitive battery, and other tests of executive function. All subjects will be evaluated with United Parkinson Disease Rating Scales (UPDRS) following an overnight withdrawal of anti-parkinson medication. Subjects will be asked to undergo an injection of \[123I\] 5-IA followed by SPECT imaging as described below. A second \[123I\] 5-IA and SPECT imaging study will be obtained for reliability testing between 2 weeks and 2 months following the initial \[123I\] 5IA imaging session.
Trial: NCT00555893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: \<=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
Trial: NCT00260026
Drug: Jin Fu Kang
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02232945
Drug: placebo of Banlangen(Radix Isatidis) granules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01026857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PLC colon release tablet 2 g/die for 4 weeks
Trial: NCT01702415
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose, intravenous solution 5mg
Trial: NCT01702415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00143273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg
Trial: NCT01947738
Drug: VBY-891
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathepsin S inhibitor
Trial: NCT01947738
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02405793
Drug: Meloxicam Test Capsules
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02405793
Drug: Meloxicam Tablets
RxNorm normalized name: Meloxicam Tablets
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00842712
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cis 80 mg/m\^2 intravenous infusion on Day 1 + Vin 25 mg/m\^2 or Cis 75 mg/m\^2 intravenous infusion on Day 1 + Gem 1250 mg/m\^2 intravenous infusion on Days 1 and 8 of each 3-week cycle will be administered along with Cil and cetuximab as per Investigator's discretion up to a maximum of 6 cycles.
Trial: NCT00421863
Drug: Triatec HCT 5
RxNorm normalized name: hydrochlorothiazide 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Trial: NCT00421863
Drug: Lasix 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Trial: NCT00421863
Drug: Catapresan TTS 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Trial: NCT00421863
Drug: Pluscor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Trial: NCT02242344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183090
Drug: Meloxicam ampoule
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02183090
Drug: Meloxicam tablet
RxNorm normalized name: Meloxicam Tablets
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00715676
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, once daily
Trial: NCT02927080
Drug: ACE-083 or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant fusion protein or normal saline.
Trial: NCT04595591
Drug: 2mg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: titration dosing speeds of propofol at 2mg/kg/min
Trial: NCT04595591
Drug: 1mg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: titration dosing speeds of propofol at 1mg/kg/min
Trial: NCT04595591
Drug: 0.5mg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: titration dosing speeds of propofol at 0.5mg/kg/min
Trial: NCT01377441
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive either 800mg IV ibuprofen or placebo pre-operatively. Post-operatively, patients will receive either 800mg IV ibuprofen or placebo 6 hours after the first dose.
Trial: NCT01377441
Drug: Placebo/Saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo pre-operatively. Post-operatively, patients will receive placebo at least 6 hours after the initial dose.
Trial: NCT00344513
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02177552
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04162327
Drug: IBI315
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive IBI315 until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.